INTRODUCTION

The vascular endothelium is defined as a single layer of endothelial cells (ECs) that line the lumen of blood vessels and are mechanically and metabolically dynamic organs. The endothelium, which consists of $1 - 6 \times 10^{13}$ individual ECs, is the largest organ in the body and exceeds $1,000 \text{ m}^2$ of estimated surface area [1-3]. This important organ is involved in a variety of physiological and pathological functions including blood supply, nutrient delivery, immune cell adhesion, vasopermeability, angiogenesis, thrombogenesis, and vascular tone [4-7].

Endothelium-dependent vasodilation is largely determined by alterations in endothelial intracellular Ca$^{2+}$ concentrations in response to mechanical stimuli (e.g., shear stress, membrane stretch) or endogenous agonists (e.g., bradykinin, ATP, or reactive oxygen species [ROS]). Increased intracellular Ca$^{2+}$ levels produces nitric oxide (NO) and prostacyclin (PGI2) that are traditionally considered as endothelium-derived relaxing factors (EDRFs) [8,9].
In addition, it has been well documented that changes in global or localized EC Ca\(^{2+}\) signaling stimulate Ca\(^{2+}\)-sensitive K\(^+\) channels and elicit the membrane hyperpolarization of ECs and vascular smooth muscle cells (VSMCs) in a sequential manner [10]. This discovery contributes to the development of a novel concept, endothelium-dependent hyperpolarization (EDH), which is a primary mechanism of vasodilation in small resistance arteries.

It is no exaggeration to state that the elucidation of EC Ca\(^{2+}\) signaling has been accomplished by the progression of sophisticated imaging techniques and fast/high-affinity fluorescent Ca\(^{2+}\) indicators, including a genetically modified mouse specifically expressing a Ca\(^{2+}\) indicator (e.g., GCaMP2) in ECs, high-quality (i.e., high speed and resolution) confocal microscopy, and total internal reflection fluorescent (TIRF) microscopy [11]. These technological advances have led investigators to explore complicated Ca\(^{2+}\) dynamics in ECs including Ca\(^{2+}\) release from the endoplasmic reticulum (ER; i.e., propagated Ca\(^{2+}\) wave [12], Ca\(^{2+}\) pulsars [13], Ca\(^{2+}\) wavelets [14]) and Ca\(^{2+}\) entry from the extracellular space (i.e., Ca\(^{2+}\) sparklets [15]) that result in vasodilation. However, the molecular mechanisms underlying the Ca\(^{2+}\) influx in ECs and their regulations have been poorly defined. In light of this, the identification of transient receptor potential factor (TRP) channels has provided new insights into Ca\(^{2+}\) mobilization in ECs that is required for EDH(F) and vasodilation. Thus, this review focuses on describing the contribution of TRP channels to fundamental Ca\(^{2+}\) signals (i.e., serve as a crucial means of altering intracellular Ca\(^{2+}\) levels) in the ECs of resistance arteries.

**Ca\(^{2+}\) SIGNALING AND EDH**

The discovery of NO and PGI\(_2\) generated from ECs has provided insight into the novel paradigm that the endothelium is an organ that does not merely cover the inner wall of blood vessels; it also controls the vascular tone and blood flow [10]. In addition, succeeding investigations have shown that EC-dependent VSMC hyperpolarization (caused by releasing factors from the ECs: endothelium-dependent hyperpolarizing factors [EDHFs]) in response to muscarinic receptor activation elicits vasodilation by inhibiting voltage-dependent Ca\(^{2+}\) channels (VDCCs) in VSMCs [16,17]. Chen and colleagues [17] sought to directly assess the effects of acetylcholine (ACh) on the membrane potential of VSMCs in the aorta and main pulmonary artery of rats. ACh-induced VSMC hyperpolarization was still detected even in the presence of inhibitors of NO or guanylyl cyclase, suggesting that EDHFs are distinct from EDRFs. Importantly, that study demonstrated that K\(^+\) efflux is a key component of EDHFs [17]. Since then, the new findings on EDHFs have evolved into a new concept of EDH; additionally, such studies have seminally identified intermediate/small conductance Ca\(^{2+}\)-sensitive K\(^+\) channels and microdomain structures (e.g., myoendothelial projections [MEPs] and myoendothelial gap junctions [MEGs]) that allow the movement of hyperpolarizing currents from ECs to VSMCs [18].

In the Garland and McPherson study [19], although VSMC hyperpolarization in response to NO was significantly attenuated by a K\(^+\) channel blocker (i.e., glibenclamide), ACh-stimulated hyperpolarization was not affected by the same blocker. The hyperpolarization and vasorelaxation induced by ACh were not sensitive to NO synthase (NOS) or cyclooxygenase (COX) inhibitors (i.e., L-NNA or indomethacin, respectively) in rat small mesenteric arteries. Further, subsequent works have demonstrated that ACh-induced hyperpolarization and vasorelaxation are associated with the activation of Ca\(^{2+}\)-sensitive IK\(_{Ca}\) and SK\(_{Ca}\) channels distributed in ECs [20-22]. This finding implies that muscarinic receptor activation evokes inositol trisphosphate (IP\(_3\))-mediated Ca\(^{2+}\) release from the ER and activates IK\(_{Ca}\)/SK\(_{Ca}\) channels. Another investigation in rat hepatic arteries showed that K\(^+\) efflux from ECs through IK\(_{Ca}\)/SK\(_{Ca}\) channels acts as an EDHF by activating inwardly rectifying K\(^+\) (K\(_i\)) channels and Na\(^+\)-K\(^+\)-ATPase in adjacent VSMCs [23]. However, since blockers of K\(_{Ca}\) channels and Na\(^+\)-K\(^+\)-ATPase (Ba\(^{2+}\) and ouabain, respectively) did not entirely abolish vasorelaxation in rat small mesenteric arteries, EC hyperpolarization might be directly transmitted to the VSMCs through MEGJs [23].

It is generally accepted that the vasorelaxation or dilation of small resistance arteries primarily depends on EDH rather than on EDRFs (e.g., NO, PGI\(_2\)) or EDHFs [18]. MEPs are defined as extensions of ECs that project through the fenestration of the internal elastic lamina (IEL) to adjacent VSMCs. The MEGJs located at the tip of the MEP are intercellular pores that allow the spread of second messengers (e.g., IP\(_3\)) or charged ions for heterocellular (EC-VSMC) communication [24]. IK\(_{Ca}\) and SK\(_{Ca}\) channels that are indispensable for EDH-mediated vasodilation in resistance arteries are activated by the binding of the Ca\(^{2+}\)-calmodulin complex to the C-terminus of those channels [25]. K\(^+\) loss via the Ca\(^{2+}\)-sensitive K\(^+\) channels elicits hyperpolarization that is conducted to VSMCs through MEGJs, which leads to vasodilation by inhibiting VDCCs (Fig. 1). Thus, it is strongly suggested that EC Ca\(^{2+}\) signaling, in particular at MEPS, plays a critical role in EDH-dependent vasodilation. Indeed, since it was first discovered that an alteration in intracellular Ca\(^{2+}\) concentrations is a major determinant of vascular reactivity [26], considerable strides have been made in understanding the role of EC Ca\(^{2+}\) signaling in EC-dependent vasodilation in resistance arteries. According to previous studies, cation-permeable TRP ion channels that allow for Ca\(^{2+}\) entry into ECs have been shown to induce EDH-mediated vasodilation in small arteries [13-15,27,28]. Thus, EC TRP channel-dependent Ca\(^{2+}\) signaling will be discussed in this review.
TRP channel-mediated Ca²⁺ signaling

The TRP superfamily is encoded by 28 genes and is classified according to DNA and protein sequence homology. Consequently, TRP channels are categorized into six subfamilies: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), and TRPV (vanilloid) channels. TRP channels are generally comprised of seven hydrophobic domains. Six (S1–S6) of the domains span the plasma membrane, and the seventh domain intracellularly exists with the COOH- and NH₂-termini of TRP channels [29-31]. The ion-conducting pore is formed immediately after the S6 domain in the subfamilies of TRPC, TRPM, and TRPV channels [32]. Although the TRP domain has been incompletely examined, it has been elucidated to date that the conserved box serves as a platform for a phosphatidylinositol 4,5-bisphosphate (PIP₂) binding site or ion channel heteromeric assembly [33,34]. The intracellular C- and N-termini of TRP channels exist for multiple regulatory elements, interaction sites, and enzymatic domains [32].

TRP channels are postulated to participate in diverse physiological processes (e.g., mechanotransduction, cellular excitability, protein trafficking, and vascular contractility) by regulating cation influx across the cell membrane [32]. TRP channels physiologically control the membrane potential and regulate Ca²⁺ signaling in ECs and VSMCs. Among TRP channel subfamilies, Na⁺-sensitive TRPV4 channels (equally permeant to K⁺, but not Ca²⁺-permeable) are activated by globally or locally increased intracellular Ca²⁺ levels in VSMCs [35]. The activated channels primarily elicit inward currents of Na⁺ in cerebral VSMCs, induce membrane depolarization, and subsequently activate VDCCs [36]. In addition to membrane potential regulation, Ca²⁺ signaling that is required for vasoconstriction or dilation is controlled by Ca²⁺-permeable TRP channels in a direct or indirect (i.e., metabotrophic) manner. For example, Ca²⁺ influx via the TRPV4 and TRPA1 channels in ECs that are directly stimulated by shear stress, endogenous lipid arachidonic acid, or exogenous agonists (e.g., GSK1016790A or AITC) triggers the vasodilation of cerebral or mesenteric arteries [15,37-39].

Localized Ca²⁺ signaling through endothelial non-selective cation TRP channels primarily plays a vital role in the generation of EDH via the downstream activation of IKCa/SKCa channels and vasodilation in small-sized resistance arteries. It is well documented that vascular peripheral resistance is a major determinant of arterial pressure and blood flow to organs and tissues. Furthermore, vascular resistance is regulated by EDH and subsequent endothelium-dependent vasodilation in the microcirculation. Indeed, impaired EDH and endothelium-dependent vasodilation in microvascular beds is found to cause cardiovascular diseases including hypertension. Thus, this review mainly focused on TRP channel-mediated EDH in resistance arteries as they are physiologically significant in the regulation of vascular resistance, intravascular pressure, and blood flow.

TRPC1

TRPC1 channels are non-selectively permeable to Ca²⁺ (a unitary conductance of ~5pS) [40]. Although TRPC1 channel is known to be expressed in the endothelium, it is debatable that TRPC1 channels show homomeric channel in intact endothelial cells. In contrast, it is definitely elucidated that TRPC1 channels form heteromeric channels with TRPC3 [41], TRPC4 [40], TRPC5 [40], and TRPV4 [42,43] channels. With regard to the role of TRPC1 channels in endothelial intracellular Ca²⁺ signaling, the activation of Ca²⁺-sensing receptor (CaSR) stimulates Ca²⁺ influx through TRPC1 channels and leads to NO production in the endothelium [44]. Furthermore, once CaSR is activated by the elevation of extracellular Ca²⁺ concentration, TRPC1 channels that are co-localized with TRPV4 channels showed vasorelaxation, which was significantly abrogated in the presence of TRPC1 and TRPV4 inhibitors [42]. Therefore, it is suggested that the heteromeric TRPC1/TRPV4 channels stimulated by CaSR activation induce NO-mediated vasorelaxation.
TRPC3

TRPC3 channels are expressed in arteriolar myocytes and contribute to membrane depolarization-induced vasoconstriction (i.e., permeability: Ca$^{2+} = \text{Na}^+ > K^+$) [45-48]. Meanwhile, growing evidence has shown that TRPC3 cation channels are expressed in ECs and are responsible for EC hyperpolarization-mediated vasodilation. The vasoreactivity of rat small mesenteric arteries was considerably blunted in response to flow or bradykinin in the treatment of TRPC3 antisense oligonucleotide [49]. Subsequent pharmacological studies with a specific inhibitor of TRPC3 channels (i.e., Pyr3) have consistently demonstrated that the ACh-induced vasodilation of human internal mammary arteries or rat mesenteric arteries is markedly reduced with Pyr3 pretreatment [50,51], implying that EC GPCR activation by shear stress or exogenous agonists is coupled to TRPC3-induced downstream signaling for vasodilation. Senadheera and colleagues used ultrastructural immunohistochemistry to show that TRPC3 channels are spatially restricted at MEPS (i.e., five-fold higher expression compared to non-MEPs) in resistance mesenteric arteries [51]. This investigation also revealed that TRPC3 inhibition with Pyr3 causes a significant reduction in EC hyperpolarization in response to ACh [51]. More recently, studies have shown that EC TRPC3 channels in cerebral arteries are translocated to the plasma membrane following purinergic receptor activation with ATP and are then involved in EDH-mediated vasodilation [52]. Collectively, it is speculated that second messengers (e.g., DAG) produced by GPCR activation stimulate Ca$^{2+}$ influx via TRPC3 channels and in turn lead to EDH-mediated vasodilation in resistance small arteries.

TRPC4

TRPC4 channels preferentially allow Ca$^{2+}$ influx in the endothelium through store-operated Ca$^{2+}$ entry and are stimulated by GPCR downstream signaling [32,53]. Freichel and colleagues [54] demonstrated that endothelium-dependent vasodilation occurs through the activation of TRPC4 channels in mouse aorta. The specific molecular mechanism underlying the vasodilation is attributed to endothelial NO synthase (eNOS) activation and NO production followed by the activation of muscarinic acetylcholine receptors [54,55]. Even though subsequent studies failed to show that endothelial store-operated Ca$^{2+}$ entry is mediated by TRPC4 channels [53,56], it is noteworthy to understand that TRPC4 channels could be involved in endothelium-dependent vasodilation in conduit arteries, but not small-sized resistance arteries.

TRPC5

TRPC5 channels show a unitary conductance of 40–60 pS and are more permeable to Ca$^{2+}$ than Na$^+$ (P$_{Ca}$/P$_{Na}$ = 1.8–9.5) [57,58]. Although the role of TRPC5 channels in endothelial function has not been clearly identified to date, previous investigations found that TRPC5 channels are distributed in the endothelium from mouse aorta, human coronary, and cerebral arteries [59-61]. Mori and colleagues revealed that Ca$^{2+}$ influx through endothelial TRPC5 channel is regulated by post-translational modifications. Specifically, S-nitrosylation, the covalent attachment of an NO to cysteine groups, enhances the activity of TRPC5 channels and Ca$^{2+}$ influx in cultured ECs [62]. However, the alteration of vasodilatory response to ACh was not monitored in mouse aortic rings originated from TRPC5 knockout models [60]. This suggests that NO-mediated vasodilation in the presence of ACh was not augmented by TRPC5 channels, which is inconsistent with previous studies [62]. Thus, it is necessary in future studies to explore if Ca$^{2+}$ entry via TRPC5 channels elicits vasodilation and via what supporting mechanisms.

TRPM2

TRPM2 channels that have a similar permeability of Ca$^{2+}$ and Na$^+$ ions display the unitary conductance of 58–76 pS [63]. The subtype of TRPM2 channels is gated by several activators including ADP-ribose, arachidonic acid, hydrogen peroxide [64-66]. The Ca$^{2+}$ influx of TRPM2 channels is also clarified to induce endothelium-dependent vasodilation. It was found in rat cremaster resistance arteries that exogenous hydrogen peroxide application leads to Ca$^{2+}$ entry and subsequent vasodilation [67]. However, those Ca$^{2+}$ signaling and vascular reactivity were markedly diminished by the treatments of TRPM2 antibody or IKCa/SKca channel inhibitors. These results indicate that hydrogen peroxide-mediated Ca$^{2+}$ entry through TRPM2 channels evokes endothelial vasodilation in the manner dependent of EDH [67].

TRPV1

TRPV1 nonselective cation channels are expressed in arterial ECs [68,69] and are favorably permeable to Ca$^{2+}$ compared with Na$^+$ (P$_{Ca}$/P$_{Na}$ = 9.6) [32]. Capsaicin, endocannabinoids, and noxious heat activate TRPV1 channels [70,71]. Anandamide-evoked TRPV1 activation increased NO in the endothelium of rat mesenteric arteries [72]. A synthetic cannabinoid compound (VSN16) induced vasorelaxation of the mesenteric arteries, which was markedly attenuated by capsazepine (a TRPV1 antagonist), L-NNA (an NOS inhibitor), charybdotoxin (an IKca/BKca channel inhibitor), or apamin (a SKca blocker) [73]. In gracilis skeletal muscle arterioles, the capsaicin-mediated stimulation of TRPV1 channels produced vasodilation that was substantially attenuated by L-NAME (an NOS inhibitor), which suggests that EC TRPV1-mediated vasodilation occurs in an NO-dependent manner [74]. Interestingly, NO-mediated vasorelaxation/dilation following TRPV1 activation differs from vasodilatory mechanisms of other TRP subfamilies (i.e., TRPV4, TRPA1) that display EDH-dependent vasodilation. In accordance with previous studies showing a
relationship between EC TRPV1 activation and NO production, capsaicin treatment increased intracellular EC Ca\(^{2+}\) levels and elicited the phosphorylation of eNOS in cultured mouse aortic ECs [75]. Additionally, the chronic administration of capsaicin profoundly increased eNOS phosphorylation at Ser\(^{177}\), NO generation, and protein kinase A (PKA) activation in mouse mesenteric arteries; these changes were absent in TRPV1 knockout mice [75]. As expected, the chronic activation of TRPV1 channels was coupled to the enhancement of EC-dependent vasorelaxation in freshly isolated mesenteric arteries [75]. Surprisingly, this study showed convincing clinical evidence that chronic capsaicin application significantly reduces blood pressure in spontaneously hypertensive rats. This finding implies that TRPV1 channels participate in the regulation of vascular tone and arterial pressure. The following study in bovine aortic ECs found that capsaicin-induced Ca\(^{2+}\) entry via TRPV1 channels stimulates Akt-calmodulin-dependent protein kinase II (CaMKII)-eNOS pathway; in turn, phosphorylated eNOS physically interacts with TRPV1 channels to produce NO [76]. However, despite consistent findings, a recent study elucidated that large renal arteries in mice do not respond to a relatively higher concentration of capsaicin (i.e., a 100-fold higher level of EC\(_{50}\) is required for significant vasodilation), whereas mesenteric small arteries showed a marked vasodilation in response to 25 nM of capsaicin [77]. Thus, the magnitude of TRPV1-dependent vasoreactivity is specific to vascular beds.

**TRPV3**

TRPV3 channels display a large unitary conductance (~150–200 pS) [78]. Dietary monoterpenoid compounds including carvacrol, eugenol, and thymol stimulate TRPV3 channels in the oral/nasal epithelium [79]. With regard to the roles of TRPV3 in EC-dependent vasodilation, Earley and co-workers revealed for the first time that carvacrol that is typically found in the Mediterranean diet, induces vasodilation in rat cerebral arteries [80]. Increased endothelial Ca\(^{2+}\) concentrations and TRPV3-like currents have been found in the presence of carvacrol [80]. Moreover, TRPV3-dependent cerebral vasodilation was found to result from VSMC hyperpolarization that was inhibited by TRAM-34, apamin, or BaCl\(_2\) (an inhibitor of inwardly rectifying K\(^{-}\) (K\(_{ir}\)) channels), but not by L-NNA or indomethacin. This suggests that TRPV3 activation-induced K\(^{-}\) efflux through IK\(_{ca}\) or SK\(_{ca}\) leads to the K\(_{ir}\)-mediated hyperpolarization of VSMCs and cerebral vasodilation [80]. Recently, it was demonstrated that EC TRPV3 Ca\(^{2+}\) sparklets (i.e., localized Ca\(^{2+}\) influx through EC TRPV3 channels) are directly and optically detected with carvacrol in the ECs of rat cerebral parenchymal arterioles [27]. The unitary Ca\(^{2+}\) events in ECs were significantly attenuated by a selective TRPV3 antagonist, isopentenyl pyrophosphate (IPP). This study also noted that TRPV3 sparklet-mediated vasodilation is not sensitive to NOS or COX inhibitors. By contrast, the inhibition of IK\(_{ca}\) or SK\(_{ca}\) channels markedly reduced the dietary compound-induced vasodilation. Importantly, the authors also suggested that the amplitude of TRPV3 channels (ΔF/F\(_{0}\) = 0.20; peak fluorescence [F] is normalized to baseline fluorescence [F\(_{0}\)]) is greater than that of TRPA1 (ΔF/F\(_{0}\) = 0.13) and TRPV4 (ΔF/F\(_{0}\) = 0.06) channels. TRPV3 Ca\(^{2+}\) sparklets were implicated to play a key role in EC Ca\(^{2+}\) signaling in cerebral resistance arterioles [27]. However, to the best of our knowledge, there have been few observations on the influence of TRPV3 channels on vasomotor reactivity. Thus, further observations are required for a better understanding of the contribution of EC TRPV3 for the modulation of vascular function.

**TRPV4**

TRPV4 channels were shown to have a specific permeability to Ca\(^{2+}\), Na\(^{+}\), and Mg\(^{2+}\) (P\(_{Ca}\)/P\(_{Na}\)/P\(_{Mg}\) = 2–3:1; P\(_{Ca}\)/P\(_{Mg}\) = 6–10:1) [68,81,82]. TRPV4 channels are stimulated by a variety of endogenous activators or synthetic agonists including 4α-phorbol 12,13-didecanoate (4α-PDD; 200 nM of EC\(_{50}\) [83]), GSK1016790A (18 nM of EC\(_{50}\) [84]), RN-1747 (4 μM of EC\(_{50}\) [85]), or arachidonic acid metabolites (e.g., 5,6-EET; 130 nM of EC\(_{50}\) [86]). When Ca\(^{2+}\)-permeable TRPV4 channels were pharmacologically activated, increased whole-cell currents or Ca\(^{2+}\) influx were observed in isolated ECs [87-90]. Previous investigations demonstrated that in small arteries, EC TRPV4-mediated alterations in Ca\(^{2+}\) levels following the activation of muscarinic or purinergic receptors in ECs contribute to marked vasodilation. ACh fails to dilate mesenteric arteries with a genetic deletion of TRPV4 channels [90]. In this study, ACh-mediated Ca\(^{2+}\) influx and NO production were also significantly blunted in TRPV4\(^{-}\) mice. Similarly, a potent TRPV4 antagonist (RN-1734) pretreatment considerably disrupted the ACh-evoked vasodilation of radial uterine arteries [91]. Sullivan et al. [92] and Sonkusare et al. [15] marked the beginning of a new area of endothelial Ca\(^{2+}\) influx through TRPV4 channels, called TRPV4 Ca\(^{2+}\) sparklets, by using improved and sophisticated optical imaging techniques including high-speed/resolution confocal or TIRF microscopy. The Sonkusare and Nelson group sought to delineate the properties of elementary TRPV4 Ca\(^{2+}\) sparklets spatially identified at MEPS. TRPV4 channels were revealed to exhibit quantal events of Ca\(^{2+}\) entry, and the quantal amplitudes were shown to be dependent on the electrochemical gradient. Surprisingly, three to eight TRPV4 sparklet sites per EC was considered firmly sufficient for maximal vasodilation [15,92]. Extensive monitoring also showed that Ca\(^{2+}\) signaling through EC TRPV4 channels is explicitly coupled to IK\(_{ca}\) and SK\(_{ca}\) activation-mediated hyperpolarization at MEPs and vasodilation [15]. Further, K\(^{-}\) efflux via IK\(_{ca}\) and SK\(_{ca}\) channels enhanced vasodilation by stimulating K\(_{ir}\) channels in ECs and VSMCs and by amplifying the hyperpolarization of both cells [23,93]. Next, one of the novel characteristics of TRPV4 sparklets is channel cooperative behavior [94]. Ca\(^{2+}\)-permeable TRPV4 channels are
Interestingly designed with a four-channel (tetramer) metastructure, the clustered TRPV4 channels locally distributed at MEPs are cooperatively gated, which is determined by protein kinase C-anchoring protein 150 (AKAP150) and intracellular Ca\(^{2+}\) [94]. It is conceivable that opening only one single TRPV4 channel may induce a minimal Ca\(^{2+}\) influx and activate a small number of IK\(_{Ca}\) and/or SK\(_{Ca}\) channels at the microdomains. However, increased cooperativity of the clustered TRPV4 channels (i.e., quantal events) gives rise to augmented Ca\(^{2+}\) amplitudes and enhanced hyperpolarization [94]. Angiotensin II-induced hypertension was shown to impair AKAP150-dependent cooperative activity of TRPV4 channels by disrupting the scaffolding protein expression at MEPs [94]. It is speculated that EC TRPV4 and AKAP150 play a critical role in preventing pathophysiological circumstances in the cardiovascular system.

With respect to the roles of TRPV channels in mechanotransduction, since ECs directly interact with shear stress induced by blood flow velocity and blood viscosity due to their unique anatomical position, considerable attention was given to flow (shear stress)-mediated EC TRPV4 activation and subsequent vasodilation in small resistance arteries. Further, because most previous studies of TRPV4 Ca\(^{2+}\) imaging were implemented in the presence of chemical agonist compounds (e.g., 4\(\alpha\)-PDD, GSK1016790A), the impact of physiological modulators including shear stress or intravascular pressure on EC TRPV4 activation and downstream signaling for vasodilation requires further exploration. TRPV4 channels activated by shear stress resulted in increased Ca\(^{2+}\) entry in the ECs of mesenteric arteries and vasodilation that was significantly suppressed in TRPV4-deficient mice [38]. Pharmacological inhibition to NOS entirely suppressed shear stress (10 dyn cm\(^{-2}\))-mediated vasodilation in mesenteric arteries [38], which was consistently shown in gracilis muscle arterioles [88]. These studies suggest that the mechanoactivation of TRPV4 channels exerts vasodilation through NO production; however, it is not completely clear as to how the channels are directly or indirectly activated by shear stress or metabolites (e.g., epoxyeicosatrienoic acids [EETs]) produced by shear stress. Conversely, the perfusion of 4\(\alpha\)-PDD and 11,12-EET still evoked vasodilation in mesenteric arteries even in the presence of NOS and COX inhibitors [72,95]. It is implied that different physiological or pharmacological forms of activation of TRPV4 channels may result in disparate downstream signaling for vasodilation [88], presumably due to the unique polymodal nature of TRPV4 channels. Further, it was delineated in human coronary arteries that flow-dependent activation of TRPV4 channels generates mitochondrial ROS (i.e., hydrogen peroxide and superoxide) that play an important role in vasodilation in human coronary arteries [96].

As mentioned above, although VSMCs are constantly exposed to intraluminal pressure, biological processes in ECs are mechanically affected by shear stress. Nonetheless, EC TRPV4 channel activity has been demonstrated to be modulated by low intravascular pressure (i.e., below 50 mmHg) in rat cremaster or mesenteric arterioles [97]. Specifically, the frequency of EC Ca\(^{2+}\) events via EC TRPV4 channels was further augmented at a low intraluminal pressure (two- to three-fold higher than those at 60–80 mmHg of arterial intraluminal pressure). Both pharmacological (i.e., selective TRPV4 agonists) and physiological (i.e., intraluminal pressure) TRPV4 activations were markedly diminished by RN1734 or HC067047 [97]. Although they revealed that TRPV4, IK\(_{Ca}\), and SK\(_{Ca}\) channels are clustered at perforations in the IEL, the inhibition of IK\(_{Ca}\) with TRAM-34 (but not the inhibition of SK\(_{Ca}\) with apamin) considerably enhanced the basal myogenic tone in cremaster arterioles. Additionally, the blockade of PLC and the IP\(_{3}\) receptor with U-73122 and xestospongin fully abrogated the low pressure-mediated increase in Ca\(^{2+}\) sparklet events. Thus, Ca\(^{2+}\) influx via EC TRPV4 channels in response to low intraluminal pressure stimulates IK\(_{Ca}\) channels through PLC and IP\(_{3}\)R signaling, which in turn leads to EC/VSMC hyperpolarization-dependent vasodilation [97].

Arachidonic acid and its metabolites are potential physiological modulators for the activation of TRPV4 channels in ECs. Arachidonic acid is converted to EETs such as 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET through cytochrome P450 (CYP) epoxygenase [86]. It has been well known that EETs have anti-hypertensive/anti-inflammatory effects and contribute to vasodilation as a prevailing EDHF [98-100]. Watanabe and colleagues [86] determined that EETs stimulate TRPV4 channels in aortic ECs and may induce vasodilation. A subsequent study elucidated that exogenous 11,12-EET application in mesenteric arteries elicited vasodilation via hyperpolarization in VSMCs, and this vasomotor activity was substantially abrogated by TRPV4 knockout or the inhibition of Ca\(^{2+}\)-sensitive K\(^{+}\) channels, but not by the blockade of NOS and COX [95]. More recently, pre-constricted human coronary arteries with endothelin-1 exhibited vasodilation in the presence of arachidonic acid, which was inhibited by RN-1734 [101]. In addition, the arachidonic acid-induced increase in Ca\(^{2+}\) concentration and vasodilation was profoundly reduced by the combination of TRAM-34 and apamin (inhibitors of IK\(_{Ca}\) and SK\(_{Ca}\) channels, respectively), the removal of extracellular Ca\(^{2+}\), or pretreatment with CYP inhibitors, suggesting that CYP-dependent metabolite generation from arachidonic acid increases Ca\(^{2+}\) influx (but not Ca\(^{2+}\) release from the sarcoplasmic reticulum) through EC TRPV4 channels and subsequently requires IK\(_{Ca}\) and SK\(_{Ca}\)-mediated hyperpolarization for vasodilation in human coronary arteries [101].

As most studies on TRPV4 channels have been performed under ex vivo preparations, many investigators have raised questions regarding the regulatory effect of TRPV4 channels on the cardiovascular system. The administration of GSK1016790A (a selective agonist for TRPV4 channels) interestingly decreased arterial pressure compared with that of control mice [103]. More-
TRPA1

TRPA1 channels are nonselective cation (i.e., Na\(^+\), Ca\(^{2+}\)) channels (but specifically permeable to Ca\(^{2+}\) compared with Na\(^+\), \(P_{\text{Ca}}/P_{\text{Na}} = 7.9\)) that have a large unitary conductance (≈ 98 pS) [106,107]. As the name of the ion channel implies, TRPA1 channels have a distinguished structure that exhibits approximately 14–19 ankyrin repeat domains in the intracellular N-terminal of the ion channels [108]. The ankyrin repeat domains participate in protein-protein interactions and modulate channel activity in response to agonists or heat [109,110]. It is well established that diverse pungent dietary compounds such as allyl isothiocyanate (AITC) from mustard, allylic from garlic, eugenol from cloves, or cinnamaldehyde from cinnamon [111] activate TRPA1 channels by exerting covalent modifications on cysteine residues of the N-terminus of the channels [112,113]. Along with the dietary activators, oxidative stress and specific metabolites of lipid peroxidation act as physiological regulators for TRPA1 channels. Previous studies determined that endogenous aldehydes, 4-hydroxy-2-nonenal (4-HNE), 4-oxononenal (4-ONE), or 4-hydroxyhexenal (4-HHE) derived from the peroxidation of 0\(\omega\)6 polysaturated fatty acids in the plasma membrane activate TRPA1 channels [114-118]. Further, hydrogen peroxide (H\(_2\)O\(_2\)) resulted in the oxidative modification of cysteine residues and subsequently activated TRPA1 channels in neuron cells [114,116]. Therefore, oxidative stress metabolites play a vital role in stimulating TRPA1 channels.

In light of the physiological consequences of TRPA1 activation, it was first noted that AITC application leads to vasorelaxation in rat mesenteric arteries by activating the target ion channels in perivascular nerves [119]. Interestingly, the AITC-mediated relaxation response was markedly attenuated after the pretreatment of the calcitonin gene-related peptide (CGRP) receptor antagonist (i.e., CGRP 8–37). Previous findings demonstrated that the dietary TRPA1 activators caused cultured trigeminal neurons to release CGRP, which was abolished by a TRPA1 channel blocker [120]. Therefore, it is likely that CGRP released from perivascular nerve endings elicits vasodilation. Subsequent studies further showed that cinnamaldehyde-mediated vasodilation in mesenteric arteries is considerably abrogated in TRPA1-deficient mice, whereas endothelial denudation has minor effects on vasodilation [121]. This suggests that pungent dietary activators of TRPA1 channels elicit vasodilation by inducing Ca\(^{2+}\) influx-dependent CGRP release from perivascular nerves and subsequently binding the peptide to CGRP receptors in VSMCs. Recently, it was reported that TRPA1 channels regulate the cold-induced vascular response [122]. Specifically, sequential vasoconstriction and vasodilation occur following local cold exposure to prevent cutaneous tissues from suffering from cold injury. Although TRPA1 channel-induced superoxide generation provoked vasoconstriction through \(\alpha_2\)-adrenoreceptor activation and myosin light chain phosphorylation immediately after environmental cold exposure, neuropeptide CGRP released from sensory nerves evoked TRPA1 channel-dependent vasodilation for the restoration of reduced blood flow [122].

Meanwhile, TRPA1 channels are identified in ECs and in perivascular or sensory nerves. However, the distribution of EC TRPA1 channels is limited to only the cerebral arteries, not the mesenteric, coronary, or renal arteries [28,37]. The direct influence of EC TRPA1 channels on the vasomotor response following the treatment of an electrophilic TRPA1 activator derived from mustard oil (e.g., AITC) was first assessed in pressurized cerebral arteries [37]. AITC concentration-dependent vasodilation of cerebral arteries was observed, which was accompanied by a significant reduction in the intracellular Ca\(^{2+}\) levels of cerebral arterial myocytes. Because VDCCs are a key determinant for Ca\(^{2+}\) dynamics in VSMCs, TRPA1 activation was suggested to induce VSMC hyperpolarization and vasodilation. TRPA1 channel-mediated vasodilation was diminished in EC-denuded arteries or after TRPA1 channel blocker (HC-030031) pretreatment [37], indicating that AITC-dependent vasodilation in cerebral arteries is EC-dependent and distinct from CGRP-induced vasorelaxation in mesenteric arteries [119]. Moreover, in intact ECs, TRPA1 channels are detected at MEPs where IK\(_{\text{Ca}}\) channels, but not SK\(_{\text{Ca}}\) channels, are locally expressed [37]. Pharmacological approaches have substantiated that although TRPA1-induced cerebral vasodilation is not affected by the inhibition of NOS and COX, the application of Ca\(^{2+}\)-sensitive K\(^+\) channel blockers or a K\(^+\) channel inhibitor markedly suppresses AITC-induced vasodilation. Thus, EC TRPA1-dependent Ca\(^{2+}\) entry (called TRPA1 Ca\(^{2+}\) sparklets) elicits a K\(^+\) efflux via IK\(_{\text{Ca}}\)/SK\(_{\text{Ca}}\) channels and provokes vasodilation through EC and VSMC hyperpolarization, which is amplified by K\(_{\text{Ca}}\) channels in cerebral arteriolar myocytes [37]. Early and co-workers extended their novel hypotheses on TRPA1 channel-induced vasodilation and revealed innovative cerebral dilatory mechanisms. They found that EC TRPA1 channels frequently display a binary channel gating behavior (i.e., two TRPA1 channels open simultaneously) [28]. Their study focused on the ROS-mediated activation of TRPA1 channels in cerebral arteries [28]. NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (NOX) was shown to generate ROS [123,124], and TRPA1 channels in neurons are stimulated by ROS or ROS-derived metabolites [114,116,125]. In cerebral arteries, the administration of exogenous NADPH-induced vasodilation that was profoundly decreased in the presence of HC-030031 or TRAM-34 [28]. Consistent with their prior study [37], the combination of L-NNA and indomethacin did not affect NADPH-induced vasodilation [28].
Collectively, NADPH-NOX downstream signaling was shown to stimulate Ca\(^{2+}\) entry via EC TRPA1 channels and subsequently led to IK\(_{\text{Ca}}\) channel-dependent vasodilation. To investigate specific signaling pathways, diverse pharmacological interventions including apocynin (an NOX inhibitor), catalase (a hydrogen peroxide-metabolizing enzyme), and deferoxamine (an inhibitor for the hydroxyl radical and lipid peroxidation) were employed in that study [28]. As a result, NADPH-mediated vasodilation was completely abolished in the presence of those inhibitors, suggesting that NOX-derived H\(_2\)O\(_2\) causes the production of lipid peroxidation metabolites, which stimulate EC TRPA1 Ca\(^{2+}\) sparklets and provoke IK\(_{\text{Ca}}\) activation-dependent vasodilation in cerebral arteries [28]. Therefore, since NOX-derived ROS production was reported to be much greater in the cerebral vasculature than in other vascular beds [126], it is strongly noted that ROS and lipid peroxidation products may serve as endogenous modulators of TRPA1 channels and physiological regulators for vasomotor reactivity in the cerebral circulation.

**CONCLUSIONS AND PERSPECTIVES**

Impaired endothelial function has been documented as a hallmark of cardiovascular disorders including hypertension, vasospasm, atherosclerosis, and coronary/cerebral ischemia. The endothelium plays an important role in the modulation of vascular contractility, which is regulated by alterations in endothelial Ca\(^{2+}\) signaling. Despite the significance of Ca\(^{2+}\) dynamics in ECs, the mechanisms underlying endothelium-dependent Ca\(^{2+}\) influx and hyperpolarization remain uncertain. In light of this, TRP channels have drawn attention to the regulation of Ca\(^{2+}\) mobilization and vascular tone via EDH-mediated vasorelaxation/dilation, as have advances in optical Ca\(^{2+}\) imaging techniques and highly sensitive Ca\(^{2+}\)-detecting molecules (e.g., fluo-4, GCaMP2 biosensor). As a result, previous groundbreaking studies have demonstrated that TRP channels participate in Ca\(^{2+}\) entry and in turn induce EDH-mediated vasodilation in small resistance arteries. However, because most of those works have utilized pharmacological agonists/antagonists to explore physiological outcomes and biophysical properties of the TRP channels under ex vivo preparation, the endogenous modulators for TRP channel-dependent endothelial Ca\(^{2+}\) signaling must be identified and the effects of biological stimuli (e.g., shear stress, intravascular pressure, stretch/tension of plasma membrane) on the activation of TRP channels in the ECs of resistance arteries must be studied. It is strongly believed that such studies will contribute to an exact understanding of the complexity of EC Ca\(^{2+}\) signaling through TRP channels and the discovery of therapeutic targets for cardiovascular disease treatments.

**ACKNOWLEDGEMENTS**

This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2017SIA5B8067020).

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**REFERENCES**

1. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. *Bioessays*. 1994;16:901-906.
2. Fishman AP. Endothelium: a distributed organ of diverse capabilities. *Ann N Y Acad Sci*. 1982;401:1-8.
3. Müller MM, Griesmacher A. Markers of endothelial dysfunction. *Clin Chem Lab Med*. 2000;38:77-85.
4. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. *J Leukoc Biol*. 2005;77:487-495.
5. Lum H, Malik AB. Regulation of vascular endothelial barrier function. *Am J Physiol*. 1994;267(3 Pt 1):L223-L241.
6. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. *Open Cardiovasc Med J*. 2010;4:302-312.
7. Sullivan MN, Earley S. TRP channel Ca\(^{2+}\) sparklets: fundamental signals underlying endothelium-dependent hyperpolarization. *Am J Physiol Cell Physiol*. 2013;305:C999-C1008.
8. Bretz DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. *Proc Natl Acad Sci U S A*. 1990;87:682-685.
9. Brotherton AF, Hoak JC. Role of Ca\(^{2+}\) and cyclic AMP in the regulation of the production of prostacyclin by the vascular endothelium. *Proc Natl Acad Sci U S A*. 1982;79:495-499.
10. Garland CJ, Hiley CR, Dora KA. EDHF: spreading the influence of the endothelium. *Br J Pharmacol*. 2011;164:839-852.
11. Pires PW, Earley S. No static at all: tuning into the complexities of Ca\(^{2+}\) signaling in the endothelium. *Circ Res*. 2016;118:1042-1044.
12. Tallini YN, Brekke JF, Shui B, Doran R, Hwang SM, Nakaj I, Salama G, Segal SS, Kotlikoff MI. Propagated endothelial Ca\(^{2+}\) waves and arteriolar dilation in vivo: measurements in Cx40BAC GCaMP2 transgenic mice. *Circ Res*. 2007;101:1300-1309.
13. Ledoux J, Taylor MS, Bonev AD, Hannah RM, Solodushko V, Shui B, Tallini Y, Kotlikoff MI, Nelson MT. Functional architecture of inositol 1,4,5-trisphosphate signaling in restricted spaces of myoendothelial projections. *Proc Natl Acad Sci U S A*. 2008;105:9627-9632.
14. Tran CH, Taylor MS, Plane F, Nagaraja S, Tsoukias NM, Solodushko V, Vigmound EJ, Furstenhaupt T, Brigidan M, Welsh DG. Endothelial Ca\(^{2+}\) waves and the induction of myoendothelial feedback. *Am J Physiol Cell Physiol*. 2012;302:C1226-C1242.
15. Sonkusare SK, Bonev AD, Ledoux J, Liedke W, Kotlikoff MI, Hopper TJ, Hill-Eubanks DC, Nelson MT. Elementary Ca\(^{2+}\) signals
through endothelial TRPV4 channels regulate vascular function. Science. 2012;336:597-601.
16. Bolton TB, Lang RJ, Takewaki T. Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea-pig anterior mesenteric artery. J Physiol. 1984;351:549-572.
17. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174.
18. Garland CJ, Dora KA. EDHF: endothelium-dependent hyperpolarization and microvascular signalling. Acta Physiol (Oxf). 2017;219:152-161.
19. Garland CJ, McPherson GA. Evidence that nitric oxide does not mediate the hyperpolarization and relaxation to acetylcholine in the rat small mesenteric artery. Br J Pharmacol. 1992;105:429-435.
20. Adeagbo AS, Triggle CR. Varying extracellular [K]^+: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol. 1993;21:423-429.
21. Holzmann S, Kukovetz WR, Windschthrofer W, Paschke E, Graier WF. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitro-L-arginine in coronary arteries. J Cardiovasc Pharmacol. 1994;23;747-756.
22. Waldron GJ, Garland CJ. Contribution of both nitric oxide and a change in membrane potential to acetylcholine-induced relaxation in the rat small mesenteric artery. Br J Pharmacol. 1994;112:831-836.
23. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K^+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
24. Kerr PM, Tam R, Ondrusova K, Mittal R, Narang D, Tran CH, Welsh DG, Plane F. Endothelial feedback and the myoendothelial projection. Microcirculation. 2012;19:416-422.
25. Lückhoff A, Pohl U, Mülsch A, Busse R. Differential role of extracellular K^+ in the rat small mesenteric artery. J Physiol. 2005;564:245-254.
26. Lückhoff A, Pohl U, Mülsch A, Busse R. Differential role of extracellular K^+ in the rat small mesenteric artery. J Physiol. 2005;564:245-254.
27. Pires PW, Sullivan MN, Pritchard HA, Robinson JJ, Earley S. Unitary TRPV3 channel Ca^2+ influx events elicit endothelium-dependent dilation of cerebral parenchymal arterioles. Am J Physiol Heart Circ Physiol. 2013;309:H2031-H2041.
28. Sullivan MN, Gonzales AL, Pires PW, Bruhl A, Leo MD, Li W, Oulidi A, Boop FA, Feng Y, Jaggar JH, Welsh DG, Earley S. Localized TRPA1 channel Ca^2+ signals stimulated by reactive oxygen species promote cerebral artery dilation. Sci Signal. 2015;8:ra2.
29. Adamian L, Liang J. Prediction of transmembrane helix orientation in polytopic membrane proteins. BMC Struct Biol. 2006;6:13.
30. Clapham DE, Runnels LW, Strübing C. The TRP ion channel family. Nat Rev Neurosci. 2001;2:387-396.
31. Vriens J, Owsianik G, Fishtalher B, Suzuki M, Janssens A, Voets T, Morisseau C, Hämmodt BD, Fleming I, Busse R, Niluss B. Modulation of the Ca^2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res. 2005;97:908-915.
32. Strübing C, Krapivinsky G, Krapivinsky L, Clapham DE. TRP3 and TRPC5 form a novel cation channel in mammalian brain. Neuron. 2001;29:645-655.
33. Strübing C, Krapivinsky G, Krapivinsky L, Clapham DE. Formaion of novel TRPC channels by complex subunit interactions in embryonic brain. J Biol Chem. 2003;278:39014-39019.
34. Greenberg HZE, Carlton-Carew SRE, Khan DM, Zargaran AK, Jahan KS, Vanessa Ho WS, Albert AP. Heteromeric TRPV4/TRPC1 channels mediate calcium-sensing receptor-induced nitric oxide production and vasorelaxation in rabbit mesenteric arteries. Vascul Pharmacol. 2017;96-98:53-62.
35. Ma X, Cheng KT, Wong CO, O’Neil RG, Birnbaumer L, Ambudkar IS, Yao X. Heteromeric TRPV4-C1 channels contribute to store-operated Ca^2+ entry in vascular endothelial cells. Cell Calcium. 2011;50:502-509.
36. Qu YY, Wang LM, Zhong H, Liu YM, Tang N, Zhu LP, He F, Hu QH. TRP1 stimulates calcium-sensing receptor-induced store-operated Ca^2+ entry and nitric oxide production in endothelial cells. Mol Med Rep. 2017;16:4613-4619.
37. Albert AP, Pucovský V, Prestwich SA, Large WA. TRPC3 properties of a native constitutively active Ca^2+-permeable cation channel in rabbit ear artery myocytes. J Physiol. 2006;571(PT 2):361-369.
38. Kamouchi M, Philipp S, Flockerzi V, Wissenbach U, Mamin A, Raemaekers L, Eggermont J, Droogmans G, Niluss B. Properties of heterologously expressed hTRP4 channels in bovine pulmonary artery endothelial cells. J Physiol. 1999;518(Pt 2):345-358.
39. Large WA, Saleh SN, Albert AP. Role of phosphoinositide 4,5-bisphosphate and diacylglycerol in regulating native TRPC channel proteins in vascular smooth muscle. Cell Calcium. 2009;45:574-582.
40. Peppati-Wildman CM, Albert AP, Saleh SN, Large WA. Endothelin-1 activates a Ca^2+-permeable cation channel with TRPC3 and TRPC7 properties in rabbit coronary artery myocytes. J Physiol.
54. Freichel M, Suh SH, Pfeifer A, Schweig U, Trost C, Weissgerber P, Shinde AV, Motiani RK, Zhang X, Abdullaev IF, Adam AP, Li Z, Guo G, Wang H, Si X, Zhou G, Xiong Y, Li S, Dai R, Yang M, Schaefer M, Plant TD, Obukhov AG, Hofmann T, Gudermann T, Jung S, Mühle A, Schaefer M, Strotmann R, Schultz G, Plant TD. Transient receptor potential canonical type 3 channels facilitate endothelium-derived hyperpolarization-mediated resistance artery vasodilator activity. *Cardiovasc. Res.* 2012;95:439-447.

55. Freichel M, Vennekens R, Olausson J, Hoffmann M, Müller C, Kochukov MY, Balasubramanian A, Abramowitz J, Birnbaumer L, Biel M, Philipp S, Freise D, Droogmans G, Hofmann F, Flockerzi V, Nilius B. Lack of an endothelial store-operated Ca\(^{2+}\) current impairs agonist-dependent vasorelaxation in TRP4\(^{-/-}\) mice. *Nat Cell Biol.* 2001;3:121-127.

56. Freichel M, Vennekens R, Olausson J, Hoffmann M, Müller C, Stolz S, Scheunemann J, Weissberger P, Biel M, Philipp S, Freise D, Droogmans G, Hofmann F, Flockerzi V, Nilius B. Lack of an endothelial store-operated Ca\(^{2+}\) current impairs agonist-dependent vasorelaxation in TRP4\(^{-/-}\) mice. *Nat Cell Biol.* 2001;3:121-127.

57. Freichel M, Vennekens R, Olausson J, Hoffmann M, Müller C, Stolz S, Scheunemann J, Weissberger P, Flockerzi V. Functional role of TRPC proteins in vivo: lessons from TRPC-deficient mouse models. *Biochem Biophys Res Commun.* 2004;322:1352-1358.

58. Shinde AV, Motiani RK, Zhang X, Abdullaev IF, Adam AP, González-Cobos JC, Zhang W, Matrougui K, Vincent PA, Trebak M. STIM1 controls endothelial barrier function independently of Orai1 and Ca\(^{2+}\) entry. *Sci Signal.* 2013;6:ra18.

59. Jung S, Mühle A, Schaefer M, Strotmann R, Schultz G, Plant TD. Lanthanides potentiate TRPC5 currents by an action across extracellular sites close to the pore mouth. *J Biol Chem.* 2003;278:3562-3571.

60. Schaefer M, Plant TD, Obukhov AG, Hofmann T, Gudermann T, Schultz G. Receptor-mediated regulation of the nonselective cation pairs agonist-dependent vasorelaxation in TRP4\(^{-/-}\) mice. *J Biol Chem.* 2000;275:17517-17526.

61. Amer MS, McKeown L, Tumova S, Liu R, Seymour VA, Wilson LA, Naylor J, Greenhalgh K, Hou B, Majeed Y, Turner P, Sedo A, O’Regan DJ, Li J, Bon RS, Porter KE, Beech DJ. Inhibition of endothelial cell Ca\(^{2+}\) entry and transient receptor potential channels by Sigma-1 receptor ligands. *Br J Pharmacol.* 2013;168:1445-1455.

62. Li Z, Guo G, Wang H, Si X, Zhou G, Xiong Y, Li S, Dai R, Yang C. TRPC5 channel modulates endothelial cells senescence. *Eur J Pharmacol.* 2017;802:27-35.

63. Li Z, Guo G, Wang H, Si X, Zhou G, Xiong Y, Li S, Dai R, Yang C. TRPC5 channel modulates endothelial cells senescence. *Eur J Pharmacol.* 2017;802:27-35.

64. Lip H, Chan WY, Leung PC, Kwan HY, Liu C, Huang Y, Michel V, Yew DT, Yao X. Expression of TRPC homologs in endothelial cells and smooth muscle layers of human arteries. *Histochem Cell Biol.* 2004;122:553-561.

65. Yoshida T, Inoue R, Mori T, Takahashi N, Yamamoto S, Harai Y, Tominaga M, Shimizu S, Sato Y, Mori Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. *Nat Chem Biol.* 2006;2:596-607.

66. Togashi K, Harai Y, Tominaga T, Higashi T, Konishi Y, Mori Y, Tominaga M. TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion. *EMBO J.* 2006;25:1804-1815.

67. Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T, Yamada H, Shimizu S, Mori E, Kudoh J, Shimizu N, Kurose H, Okada Y, Imoto K, Mori Y. LTRPC2 Ca\(^{2+}\)–permeable channel activated by changes in redox status confers susceptibility to cell death. *Mol Cell.* 2002;9:163-173.

68. Kolisek M, Beck A, Fleig A, Penner R. Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation of TRPM2 channels. *Mol Cell.* 2005;18:61-69.

69. Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, Schmitz C, Stokes AJ, Zhu Q, Bessman MJ, Penner R, Kinet JP, Scharenberg AM. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. *Nature.* 2001;411:595-599.

70. Chidgey J, Fraser PA, Aaronson PI. Reactive oxygen species facilitate the EDH response in arterioles by potentiating intracellular endothelial Ca\(^{2+}\) release. *Free Radic Biol Med.* 2016;97:274-284.

71. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Itô Y. Transient receptor potential channels in cardiovascular function and disease. *Circ Res.* 2006;99:119-131.

72. Yao X, Garland CJ. Recent developments in vascular cell transient receptor potential channels. *Circ Res.* 2005;97:853-863.

73. Bayliss RL, Brayden JE. TRPV channels and vascular function. *Acta Physiol (Oxf).* 2011;203:99-116.

74. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature.* 1997;389:816-824.

75. Poblete IM, Orliac ML, Briones R, Adler-Graschinsky E, Huidobro-Toro JP. Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. *J Physiol.* 2005;568(Pt 2):539-551.

76. Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennet T, Baker D, Selwood DL, Hiley CR. Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-(N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. *Br J Pharmacol.* 2007;152:751-764.

77. Kark T, Bagi Z, Lízánecz E, Pásztor ET, Erdéi N, Czikora A, Papp Z, Eses I, Pórszázn R, Tóth A. Tissue-specific regulation of microvascular diameter: opposite functional roles of neuronal and smooth muscle located vanilloid receptor-1. *Mol Pharmacol.* 2008;73:1405-1412.

78. Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J, He H, Zhao Z, Cao T, Yan Z, Liu D, Arendshorst WJ, Huang Y, Tepel M, Zhu Z. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. *Cell Metab.* 2010;12:130-141.

79. Ching LC, Kou YR, Shuye SK, Su KH, Wei J, Cheng LC, Yu YB, Pan CC, Lee TS. Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. *Cardiovasc Res.* 2011;91:492-501.

80. Chen L, Kaßmann M, Sendeski M, Tsvetkov D, Marko L, Michalick L, Riehle M, Liedtke WB, Kuebler WM, Harteneck C, Tepel M, Patzak A, Gollasch M. Functional transient receptor potential...
vanilloid 1 and transient receptor potential vanilloid 4 channels along different segments of the renal vasculature. Acta Physiol (Oxf). 2015;213:481-491.

78. Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ. 2-aminophosphoethanolamine borate activates and sensitizes the heat-gated ion channel TRPV3. J Neurosci. 2004;24:S175-S182.

79. Xu H, Delving M, Jun JC, Clapham DE. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006;9:628-635.

80. Earley S, Gonzales AL, Garcia ZI. A dietary agonist of transient receptor potential cation channel V3 elicits endothelium-dependent vasodilation. Mol Pharmacol. 2010;77:612-620.

81. Randhawa PK, Jaggi AS. TRPV1 and TRPV4 channels: potential targets for ischemic conditioning-induced cardioprotection. Eur J Pharmacol. 2015;746:180-185.

82. Strotmann R, Harteneck C, Nunnenmacher K, Schultz G, Plant TD. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol. 2000;2:695-702.

83. Watanabe H, Davis JB, Smart D, Jerman JC, Smith GD, Hayes P, Vrien J, Cairns W, Wissenbach U, Preen J, Flockerzi V, Droogmans G, Benham CD, Nilius B. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002;277:13569-13577.

84. Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping N, et al. N-((1S)-1-[[4-((2S)-2-[[2,4-dichlorophenyl)sulfonyl]amino]-3-hydroxypropanoyl]1-piperazinyl]carbonyl]-3-methylbutyl]-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: part I. J Pharmacol Exp Ther. 2008;326:432-442.

85. Vincent F, Acevedo A, Nguyen MT, Dourado M, DeFalco J, Gustafson A, Spiro P, Emerling DE, Kelly MG, Duncton MA. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009;389:490-494.

86. Watanabe H, Vrien J, Preen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003;424:434-438.

87. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grigic I, Harteneck C, Liedtke W, Hoyer J, Köhler R. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS One. 2007;2:e827.

88. Köhler R, Heyken WT, Heinau P, Schubert R, Si H, Kacik M, Busch C, Grigic I, Maier T, Hoyer J. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilation. Arterioscler Thromb Vasc Biol. 2006;26:1495-1502.

89. Watanabe H, Vrien J, Suh SH, Benham CD, Droogmans G, Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells. J Biol Chem. 2002;277:4044-4051.

90. Zhang DX, Mendoza SA, Babolz AH, Mizuno A, Ge ZD, Li R, Warltier DC, Suzuki M, Gutterman DD. Transient receptor potential vanilloid subtype 4-deficient mice exhibit impaired endothelium-dependent relaxation induced by acetylcholine in vitro and in vivo. Hypertension. 2009;53:532-538.

91. Senadheera S, Bertrand PP, Grayson TH, Leader L, Murphy TV, Sandow SL. Pregnancy-induced remodelling and enhanced endothelium-derived hyperpolarization-type vasodilator activity in rat uterine radial artery: transient receptor potential vanilloid type 4 channels, caveolae and myoendothelial gap junctions. J Anat. 2013;223:677-686.

92. Sullivan MN, Francis M, Pitts NL, Taylor MS, Earley S. Optical recording reveals novel properties of GSK1016790A-induced transient receptor potential channel TRPV4 activity in primary human endothelial cells. Mol Pharmacol. 2012;82:464-472.

93. Sonkusare SK, Dalsgaard T, Bone AD, Nelson MT. Inward rectifier potassium (Kir2.1) channels as end-stage boosters of endothelium-dependent vasodilators. J Physiol. 2016;594:3271-3285.

94. Sonkusare SK, Dalsgaard T, Bone AD, Hill-Eubanks DC, Kottiikoff MJ, Scott JD, Santana LF, Nelson MT. AKAP150-dependent cooperative TRPV4 channel gating is central to endothelium-dependent vasodilation and is disrupted in hypertension. Sci Signal. 2014;7:ra66.

95. Earley S, Pauyo T, Drapp R, Tavares MJ, Liedtke W, Brayden JE. TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure. Am J Physiol Heart Circ Physiol. 2009;297:H1096-H1102.

96. Babolz AH, Mendoza SA, Zheng X, Zinkevich NS, Li R, Gutterman DD, Zhang DX. Activation of endothelial TRPV4 channels mediates flow-induced dilation in human coronary arteries: role of Ca²⁺ entry and mitochondrial ROS signaling. Am J Physiol Heart Circ Physiol. 2012;302:H634-H642.

97. Bagher P, Beleznai T, Kansui Y, Mitchell R, Garland CJ, Dora KA. Low intravascular pressure activates endothelial cell TRPV4 channels, local Ca²⁺ events, and IK₆ channels, reducing arteriolar tone. Proc Natl Acad Sci U S A. 2012;109:18174-18179.

98. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.

99. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.

100. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:1244-1253.

101. Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, Zhang DX. Arachidonic acid-induced dilation in human coronary arteries: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca²⁺ entry. J Am Heart Assoc. 2013;2:e000080.

102. Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulzpio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, et al. Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: part 2. J Pharmacol Exp Ther. 2008;326:443-452.

103. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensitization in mice lacking TRPV4. J Biol Chem. 2003;278:22664-22668.

104. Nishijima Y, Zheng X, Lund H, Suzuki M, Mattson DL, Zhang DX. Characterization of blood pressure and endothelial function in
TRPV4-deficient mice with L-NAME- and angiotensin II-induced hypertension. *Physiol Rep.* 2014;2:e00199.

105. Félatou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? *Arterioscler Thromb Vasc Biol.* 2006;26:1215–1225.

106. Karashima Y, Prenej J, Talavera K, Janssens A, Voets T, Nilius B. Agonist-induced changes in Ca$^{2+}$ permeation through the nociceptor cation channel TRPA1. *Biophys J.* 2010;98:773–783.

107. Nagata K, Duggan A, Kumar G, García-Añoveros J. Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. *J Neurosci.* 2005;25:4052–4061.

108. Earley S. TRPA1 channels in the vasculature. *Br J Pharmacol.* 2012;167:13–22.

109. Cordero-Morales JF, Gracheva EO, Julius D. Cytoplasmic ankyrin repeats of transient receptor potential A1 (TRPA1) dictate sensitivity to thermal and chemical stimuli. *Proc Natl Acad Sci U S A.* 2011;108:E1184–E1191.

110. Sedgwick SG, Smerdon SJ. The ankyrin repeat: a diversity of interactions on a common structural framework. *Trends Biochem Sci.* 1999;24:311–316.

111. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron.* 2004;41:849–857.

112. Hinman A, Chuang HH, Bautista DM, Julius D. TRP channel activation by reversible covalent modification. *Proc Natl Acad Sci U S A.* 2006;103:19564–19568.

113. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. *Nature.* 2007;445:541–545.

114. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. *Neurosci.* 2008;27:1131–1142.

115. Taylor-Clark TE, McAlester MA, Nassenstein C, Sheard SA, Wilson S, Thornton J, Carr MJ, Undem BJ. Relative contributions of TRPA1 and TRPV1 channels in the activation of vagal bronchopulmonary C-fibres by the endogenous autacoid 4-oxononalen. *J Physiol.* 2008;586:3447–3459.

116. Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R, Campi B, Imamachi N, André E, Patacchini R, Cottrell GS, Gatti R, Bashaum AI, Bunnett NW, Julius D, Geppetti P. 4-Hydroxynonalen, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. *Proc Natl Acad Sci U S A.* 2007;104:13519–13524.

117. Earley S, Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Högestätt ED, Julius D, Jordt SE, Zygmunt PM. Pungent products from garlic activate the sensory ion channel TRPA1. *Proc Natl Acad Sci U S A.* 2005;102:12248–12252.

118. Kunkler PE, Ballard CJ, Oxford GS, Hurley JH. TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation. *Pain.* 2011;152:38–44.

119. Pozsgai G, Bodkin JV, Graepel R, Bevan S, Andersson DA, Brain SD. Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. *Cardiovasc Res.* 2010;87:760–768.

120. Aubdool AA, Graepel R, Kodji X, Alawi KM, Bodkin JV, Srivastava S, Gentry C, Heads R, Grant AD, Fernandes ES, Bevan S, Brain SD. TRPA1 is essential for the vascular response to environmental cold exposure. *Nat Commun.* 2014;5:5732.

121. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. *J Clin Invest.* 1973;52:741–744.

122. Miller AA, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: are they all bad? *Antioxid Redox Signal.* 2006;8:1113–1120.

123. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. *Prog Lipid Res.* 2003;42:318–343.

124. Miller AA, Drummond GR, Schmidt HH, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. *Circ Res.* 2005;97:1055–1062.